Join
Live feed
·
PRReleasevia Quantisnow
GRI Bio Inc. logo

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

ByQuantisnow·Wall Street's wire, on your screen.
GRI· GRI Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GRI (GRI Bio Inc.) and more on Quantisnow.